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Factors Associated With Recurrence of Varicose Veins After Thermal
Ablation: 3-Year Results of the REVATA (Recurrent Veins After
Thermal Ablation) Study
R.G. Bush1, P. Bush1, J. Flanagan2, R. Fritz3, T. Gueldner4, J. Koziarski5,
K. McMullen6, G. Zumbro7, 1Midwest Vein & Laser Center, Centerville,
Ohio, 2Delaware Valley Vein Center, Phoenixville, Pa, 3Advanced Vein
Center of North Texas, Irving, Tex, 4Wisconsin Vein Center, Manitowoc,
Wisc, 5Family Surgical, Battlecreek, Mich, 6Varicose Vein Clinics of Okla-
homa, Oklahoma City, Okla, 7Vein Specialists of Augusta, Martinez, Ga
Background: Factors contributing to recurrence of varicose veins after
thermal ablationarenotwell known.Thegoalof thisprospective,non-randomized,
multi-center trial was to determine the site, source, and contributory factors of
varicose vein recurrence after radiofrequency (RF) and laser ablation.
Methods: Seven centers enrolled patients into the study during a
twelve-month period, from January 1st, to December 31st, 2010. All
patients underwent previous thermal ablation of the great saphenous vein
(GSV), small saphenous vein (SSV) or anterior accessory great saphenous
vein (AAGSV). Patients with high ligation of the GSV and/or stripping were
excluded from the study. From a specific designed study tool, recurrence was
identified as to site, etiology, and primary mode of treatment (RF, laser).
Results: 2,380 patients were evaluated during this time frame. A total of
164 patients, (7%), 3 with bilateral limb involvement, had varicose vein recur-
rence at a mean of 3 years after treatment (range, 9 months to 8 years) This
group of 164 patients with varicose vein recurrence were the subjects of this
study. 33% were between the age of 51 and 60, median age range was 51-60,
and 83%were women. A history of deep venous thrombosis (DVT)was present
in 2% of the patients and deep venous insufficiency was present in 17%. GSV
ablationwas the initial treatment in 159 patients (RF: 33, laser: 131, 52 of these
patients had either SSV or AAGSV ablation concurrently. Total or partial GSV
recanalization occurred in 47 patients (29%). Of these 47 patients, 27 had RF
ablation, and 20 had laser thermal ablation. New AAGSV reflux occurred in 40
patients (24%), and new SSV reflux occurred in 24 patients (12%) Primary or
associated perforator pathology was present in 64% of patients.
Conclusions: Recurrence of varicose veins at 3 years after thermal
ablation was 7%. The three most important factors associated with varicose
vein recurrence included new or recurrent perforating veins; recanalized
GSV and new AAGSV reflux, in decreasing frequency. In this study, patients
who underwent RF treatment had a higher rate of GSV recanalization than
those who were treated with laser.
Cyanoacrylate Glue Great Saphenous Vein Ablation: Preliminary 180-
Day Follow-Up of a First-In-Man Feasibility Study of a No-Compres-
sion-No-Local-Anesthesia Technique
J.I. Almeida1, J.J. Javier2, E.G. Mackay3, C. Bautista4, T. Proebstle5,
1Miami Vein Center, Miami, Fla, 2Physicians Regional Vein Center, Naples,
Fla, 3Mackay Vein Center, St. Petersburgh, Fla, 4Canela Clinic, La Romana,
Dominican Republic, 5University Clinic of Mainz, Mainz, Germany
Background: Endovenous thermal ablation is a highly effective tech-
nology for the treatment of incompetent great saphenous veins (GSVs).
However, the treatment requires painful transcutaneous injection of
perivenous anesthetic fluids. Graduated compression hose are required
postprocedure to help mitigate the inflammatory side-effects of thermal
delivery. This study was conducted to demonstrate the safety and efficacy of
the Sapheon Closure System for chemical ablation of duplex proven incom-
petent great saphenous veins.
Methods: Two series of patients were treated (n8 and n30
follow-up of 180 and 30 days, respectively). After venous access and place-
ment of a novel delivery system, the vein was sealed with a proprietary
cyanoacrylate (CA) formulation. Perivenous tumescent anesthesia and post-
procedure compression stockings were omitted.
Results: Thirty-eight patients (29 female) with a median age of 51
years (range, 26-77) and an average VCSS score of 6.0 /2.7 (range,
2-17) received study treatment. Average maximum saphenofemoral junc-
tion (SFJ) diameter was 8.0 / 2.2 cm (range, 4.1 - 12.0) before
treatment. The mean length of ablated GSV segments was 33cm (range,
15-52), average treatment duration was 20.3 minutes (range, 11 - 33). The
mean volume of CA delivered was a total of 1.3 ml (range, 0.63 - 2.25).
Immediately postprocedure, and at 24-72 hours, 100% (38 of 38) were
closed. At 30 days follow-up 97% (35 of 36) of treated GSV segments were
completely closed; one limb had a 1cm segment of incomplete ablation.
VCSS scores improved to a mean of 1.9 /2.1 (range, 0-11; P.001
compared to baseline) at 30 days in 37 patients. Of the eight patients
followed for 180 days, average VCSS improved to 1.1 / 1.0 (range, 0 -
3) Thirty-one of 37 patients reported no pain during the 30 days after
treatment; the remaining six were successfully treated with NSAIDs. No
significant side effects or complications were observed.
Conclusion: Endovenous ablation of incompetent GSVs with a CA-
based glue is feasible. Procedure times are short, tumescent anesthesia is
unnecessary as are postprocedure compression stockings. Lack of significant
side-effects and an initial success rate of 100% with significant, long-stand-
ing, improvement of clinical symptoms support further clinical studies.
The Long-Term Effect of Foam Sclerotherapy On Chronic Venous Leg
Ulcers With Superficial Venous Reflux
F.J. Slim, S.R. Kulkarni, L.G. Emerson, C. Davies, R.A. Bulbulia,
M.R. Whyman, K.R. Poskitt, Cheltenham General Hospital, Cheltenham,
United Kingdom
Background: The ESCHAR trial showed that superficial venous sur-
gery and compression in chronic venous ulcers achieved a 24 week healing
rate of 65%, 12 month recurrence rate of 12% and 4 year recurrence rate of
31%. Foam sclerotherapymay be an attractive alternative to surgery. The aim
of this study is to assess the effect of foam sclerotherapy on ulcer healing and
long term recurrence in chronic venous leg ulcers. This is an expanded study
of the abstract presented at the Royal Society of Medicine Venous Forum
reporting long term recurrence data.
Methods: Chronic venous leg ulcers (CEAP 5 and CEAP 6) with
superficial venous reflux were treated between March 2006 and August
2011 with ultrasound guided foam sclerotherapy and compression. Venous
duplex was performed on all legs before and one week after treatment.
24-week ulcer healing and 1 and 4 year ulcer recurrence rates were analysed
using Kaplan-Meier survival analysis.
Results: Two hundred and fourteen legs (199 patients) with chronic
venous ulcers (CEAP 5: n173, CEAP 6: n41) were treated with foam
sclerotherapy. Median age was 73 years (range, 29-92, M:F  87:112).
Complete occlusion was achieved in 195/214 (91.1%) legs, short segment
occlusion in 16/214 (6.5%) legs and 3/214 failed to occlude. One patient
suffered nonocclusive DVT diagnosed on duplex scan at 1 week and one
presented with an occlusive DVT at 3 weeks following a normal scan at 1
week. One patient developed asymptomatic occlusive DVT at two weeks
following a nonocclusive DVT diagnosed on initial 1 week scan. Eighteen
patients were lost to follow up (3 moved away and 15 died of unrelated
cause). Twenty four week healing rate was 70.7% and 1 and 4 year recurrence
rate were 4.7% and 28.1% respectively.
Conclusion: Foam sclerotherapy is effective in abolition of superficial
venous reflux contributing to favourable ulcer healing and long term recur-
rence rates. Foam sclerotherapy is an attractive alternative to superficial
venous surgery in this group of patients.
Occlusion RateWith Foam Sclerotherapy For the Treatment of Greater
Saphenous Vein Incompetence: A Multicentric Study of 3170 Cases
J.H. Ulloa, Jr, Clinica de Venas, Bogota, Colombia
Background: Foam sclerotherapy using direct access under guided
ultrasound, has been the method of choice of our group for the treatment of
greater saphenous vein (GSV) incompetence for the last 8 years. The
practicality of this approach, low costs, no anesthesia requirement and
repeatability, has encouraged other groups in Latin America to follow our
example. We organized a multicentric international group in order to get
mutual feedback to improve our technique and establish the potential
hazards we may encounter.
Methods: We present a prospective multicentric study where 2674
patients, 3170 limbs, C2-6, Ep,As,Pr, diagnosed with duplex scanning and
operated between june 2007 and june 2011. All cases were treated with
foam sclerotherapy with no other treatment associated. Lapidium clo-
rhidrate was the sclerosant of choice due to its increased foam stability. Foam
was delivered into the vein via a 21-gauge needle just below the knee; an
average of 3cc (12cc of foam) per patient was used. Compression stockings
(22mmHg) were used in all cases. Follow-up visits were scheduled at the first
week, first,3rd,6th and 12th months and included ultrasound surveillance to
assess the occlusion of the treated vein.
Result: Occlusion of the GSV was achieved in 96.2% of limbs studied
and 93.7% remain occluded at 12months after treatment. Among the
complications we had three DVT, one of them subclinical. Superficial
thrombophlebitis in 17, induration in 390 and dyschromia in 46 cases. We
had one major incident: a neumonitis that required ICU hospitalization for
5 days and were successfully discharged.
Conclusions: Foam sclerotherapy is a safe method that showed a high
occlusion rate. The possibility of adverse effects has to be taken into account in
order to minimize risks and be prepared to handle unavoidable complications.
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